The cardioprotective effects of heart failure treatments in patients with cancer were demonstrated today in a presentation at ...

Panelists discuss how effective heart failure management requires collaborative care across multiple specialties (primary care, cardiology, endocrinology, nephrology) with advanced practice providers ...

Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...

Adults who have heart failure with a left ventricular ejection fraction of 40% or more face a high risk of hospitalization for heart failure and cardiovascular death. People who have heart failure ...

The researchers of a recent British Medical Journal paper reviewed heart failure diagnosis and management data. Heart failure has led to considerable health and financial burdens globally, especially ...

When the heart struggles to pump efficiently, a cascade of events unfolds. Fluid accumulates in the lungs and extremities. Breathing becomes labored. Simple activities like climbing stairs or carrying ...

Advanced heart failure is when heart failure progresses to the most severe stage. When you have advanced heart failure, your blood pressure, blood flow, kidney and liver function, exercise capacity, ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

An increasing proportion of patients with heart failure receive a combination of four medications shown to improve prognosis and recommended in guidelines. However, there is still room for improving ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally, sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...